Benefits
Mild GI symptom relief: single-arm 6-week trial (uncontrolled)
In adults with mild GI symptoms consuming a typical Western diet, 600 mg ButiShield once daily was reported efficacious and well-tolerated, with no serious adverse events. This was a single-arm study of 20 people with no placebo group, so the improvement over 6 weeks cannot be separated from natural symptom fluctuation or a placebo response. Primary outcome was change in GI symptom severity (indigestion domain of the Gastrointestinal Symptom Rating Scale).
Digestion-associated quality of life
The same single-arm trial also measured Digestion-associated Quality of Life. Because there was no placebo comparator, any change in this score cannot be attributed to the supplement with confidence, and no separate extra-intestinal benefit was demonstrated.
Intestinal barrier (preclinical mechanism, not measured for ButiShield)
Butyrate can influence intestinal barrier proteins in laboratory and animal models. This is a general property of the butyrate molecule described in preclinical research, not an intestinal-barrier outcome measured for ButiShield in people. Leaky gut is a non-medical marketing term, and no barrier-function benefit was demonstrated in the ButiShield trial.
Primary energy source for colonocytes
Butyrate provides energy to healthy intestinal cells (colonocytes) — it's actually the primary energy source for these cells, accounting for ~70% of their energy requirement. Supports colonocyte health, proliferation, and normal turnover. Mechanism supports overall colon health beyond symptomatic gut comfort.
Microbiome and signaling molecule role
Butyrate supports intestinal and digestive health by supporting healthy microbiome and serving as a signaling molecule to regulate numerous metabolic processes at the cellular level. The signaling functions extend butyrate's applications beyond pure local gut effects to broader metabolic and inflammatory regulation.
Mechanism of action
Colonocyte primary energy substrate
Butyrate provides ~70% of the energy requirement of colonocytes (large intestine cells) — far more important than glucose or other fuels for these specific cells. Adequate butyrate supply supports colonocyte health, normal turnover, and barrier function. Mechanism explains butyrate's foundational role in gut health.
Tight junction protein upregulation
Butyrate selectively upregulates tight junction proteins (claudin, occludin, ZO-1) and facilitates tight junction assembly via AMPK activation. Tight junctions seal intestinal epithelial cells together — preventing uncontrolled passage of substances from gut to circulation ('leaky gut'). Mechanism supports barrier integrity.
HDAC inhibitor signaling
Butyrate is a known histone deacetylase (HDAC) inhibitor — affecting gene expression and cellular signaling. HDAC inhibition is the same mechanism class as several pharmaceutical agents. Mechanism contributes to butyrate's diverse effects beyond pure energy substrate role. Gene-expression effects have been observed in laboratory research.
Microbiome modulation
Butyrate supports beneficial gut bacteria growth while competing with pathogenic bacteria. Healthy microbiome produces more butyrate, creating positive feedback — but low-fiber diets disrupt this cycle. Supplemental butyrate via ButiShield can help restore healthy microbiome balance.
MicroPEARLS spray-freezing technology
Kemin's proprietary spray-freezing technology creates microparticles with sustained release properties. The physical encapsulation protects butyrate from rapid upper-GI absorption and degradation — enabling delivery to the distal small intestine and colon where it's needed. Technology distinguishes from generic butyrate formulations.
Clinical trials
Single-arm 6-week clinical trial evaluating ButiShield efficacy, safety, and tolerability in healthy adults with mild GI symptoms consuming typical Western diet. Reviewed by Sterling Institutional Review Board, study run by BioFortis. Clinical Trial Registration NCT06397482. Primary outcome: change in GI symptom severity (Gastrointestinal Symptom Rating Scale - indigestion domain).
20 participants (75% female) with mild GI symptoms consuming typical Western diet. 6-week single-arm intervention with 600 mg ButiShield/day.
ButiShield was efficacious and well-tolerated, with no serious adverse events. Effects on GI symptom severity (indigestion domain), digestion-associated quality of life (DQLQ), intestinal permeability biomarkers, hematology, and clinical chemistry. Highlighted ButiShield as promising novel solution for intestinal and extra-intestinal health plus quality of life enhancement.
Class evidence from extensive butyrate research base. Studies include Donohoe et al. (microbiome and butyrate regulate energy metabolism and autophagy in mammalian colon, published in Cell Metabolism), Yan and Ajuwon (butyrate modifies intestinal barrier function in IPEC-J2 cells, PLoS One), and Peng et al. (butyrate enhances intestinal barrier via tight junction assembly).
Various — preclinical and clinical research base for butyrate's effects on intestinal health.
Butyrate supports intestinal cell energy metabolism, barrier function via tight junction upregulation, microbiome balance, and metabolic regulation. Extensively researched short-chain fatty acid with well-documented physiological roles. Foundation for ButiShield's mechanism positioning.
Literature review by Banasiewicz et al. published in Gastroenterology Review/Przegląd Gastroenterologiczny 2020. Determination of butyric acid dosage based on clinical and experimental studies. Establishes the appropriate dose range for clinical applications.
Not applicable — literature review of butyric acid clinical and experimental dosing.
Established appropriate butyric acid dosing for clinical applications across multiple intestinal health indications. Provides clinical foundation for ButiShield's 600 mg dose (≥210 mg butyric acid). Literature review reinforces the well-characterized nature of butyrate as a therapeutic compound.